Company intelligence / Profile preview

Emulate

Boston, Massachusetts, United States

Ownership: Private
Employees: ~133
Development stage: Commercial

Overview

Emulate’s Organs-on-Chips technology has demonstrated improved prediction of human drug-induced liver injury compared to animal models and hepatic spheroids. Their Liver-Chip has been validated in peer-reviewed studies for predictive toxicology and mechanism-of-action research. The technology supports precision medicine initiatives and regulatory science collaborations with the FDA.

Therapeutic areas: OtherOncology
Modalities: Device (Organ-on-a-Chip)Microphysiological system (MPS)In vitro model system
Industry: Non-Drug Biotech

Partnerships

RocheTakedaU.S. Food and Drug Administration

Beyond the preview

Go deeper on Emulate.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emulate.

Explore the full profile